Company: MIRA
Filing Date: 2025-05-28
Form Type: 8-K
Source: 0001641172-25-012603
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-05-28
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

On
May 28, 2025, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) (“ MIRA” or the “ Company”) announced that it will participate
in the BIO International Convention 2025, taking place in Boston, Massachusetts from June 16 - 19, 2025

Separately,
the Company is providing an update on the continued advancement of its clinical and preclinical programs. MIRA’s lead candidate, Ketamir-2 Phase IIa
clinical trial in neuropathic pain by the end of 2025 non-opioid alternative

The
Company is also conducting preclinical studies evaluating Ketamir-2 in models of post-traumatic stress disorder (PTSD) and assessing
the efficacy of a previously developed topical formulation

In
addition, MIRA is finalizing regulatory filings related to its previously announced acquisition of SKNY Pharmaceuticals, Inc. SKNY-1 smoking cessation and obesity CB1, CB2, and MAO-B

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                    MIRA                                          
  Dated:            By:                        /s/                
                    Name:                      Erez               
                    Title:                     Chief